Transplant Statistics: Annual Report

	Year of Transplant
	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Total # of Post-Tx Malignancies	125	144	165	179	136	133	141	142	71	33
Malignancies by Type	66	91	105	86	72	71	74	72	38	17
Squamous/Basal Cell Carcinoma
Melanoma	7	2	2	6	4	4	4	2	-	-
Kaposi Sarcoma	-	2	1	3	2	2	-	7	2	1
Central Nervous System	1	1	-	-	5	-	2	-	1	-
Genito-Urinary (1)	11	12	14	14	8	7	20	12	9	3
Gastro-Intestinal (2)	10	12	12	28	17	20	16	21	6	5
Primary Hepatic Tumor	-	-	1	1	1	2	2	-	1	-
Metastatic Hepatic Tumor	1	-	2	1	1	1	1	5	-	-
Larynx/Bronchi/Lung	7	4	6	14	7	9	8	8	6	3
Breast/Thyroid/Adrenal	8	8	7	8	6	8	9	6	5	1
Leukemia	-	-	1	1	-	2	-	-	-	-
Sarcoma (3)	2	-	3	-	1	-	1	1	-	-
Other	11	12	9	14	8	6	2	7	3	3
Unknown	1	-	2	3	4	1	2	1	-	-
Malignancies by Type(%)	52.8%	63.2%	63.6%	48.0%	52.9%	53.4%	52.5%	50.7%	53.5%	51.5%
Squamous/Basal Cell Carcinoma
Melanoma	5.6%	1.4%	1.2%	3.4%	2.9%	3.0%	2.8%	1.4%	-	-
Kaposi Sarcoma	-	1.4%	0.6%	1.7%	1.5%	1.5%	-	4.9%	2.8%	3.0%
Central Nervous System	0.8%	0.7%	-	-	3.7%	-	1.4%	-	1.4%	-
Genito-Urinary (1)	8.8%	8.3%	8.5%	7.8%	5.9%	5.3%	14.2%	8.5%	12.7%	9.1%
Gastro-Intestinal (2)	8.0%	8.3%	7.3%	15.6%	12.5%	15.0%	11.3%	14.8%	8.5%	15.2%
Primary Hepatic Tumor	-	-	0.6%	0.6%	0.7%	1.5%	1.4%	-	1.4%	-
Metastatic Hepatic Tumor	0.8%	-	1.2%	0.6%	0.7%	0.8%	0.7%	3.5%	-	-
Larynx/Bronchi/Lung	5.6%	2.8%	3.6%	7.8%	5.1%	6.8%	5.7%	5.6%	8.5%	9.1%
Breast/Thyroid/Adrenal	6.4%	5.6%	4.2%	4.5%	4.4%	6.0%	6.4%	4.2%	7.0%	3.0%
Leukemia	-	-	0.6%	0.6%	-	1.5%	-	-	-	-
Sarcoma (3)	1.6%	-	1.8%	-	0.7%	-	0.7%	0.7%	-	-
Other	8.8%	8.3%	5.5%	7.8%	5.9%	4.5%	1.4%	4.9%	4.2%	9.1%
Unknown	0.8%	-	1.2%	1.7%	2.9%	0.8%	1.4%	0.7%	-	-
Total # of Patients	99	118	121	141	107	114	121	115	63	29

Source: OPTN/SRTR Data as of August 1, 2001.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Patients may have more than one posttransplant malignancy reported due to multiple follow-up forms.